Inhibiting Coronavirus Replication

The Pfizer US Medical Affairs Antiviral Team invites you to participate in an educational webinar series titled "Inhibiting Coronavirus Replication" focused on providing education on COVID-19 and nirmatrelvir tablets; ritonavir tablets (PAXLOVIDTM). The webinar series is designed to communicate important information on nirmatrelvir tablets; ritonavir tablets (PAXLOVID) for the treatment of mild-to-moderate COVID-19.

The webinar series will also include a live question-and-answer session with Pfizer medical experts.

We are hosting a "Inhibiting Coronavirus Replication" session on the topic below.

Recent Updates and Data about a COVID-19 Oral Antiviral

Speaker: Ashley S. Cha-Silva, PharmD, MS
Director, Value & Evidence, COVID Antiviral
Global Access & Value (GAV), Pfizer

Speaker: Bryan D. Lizza, PharmD, MS
Field Medical Director, Antivirals
US Field Medical Affairs, Pfizer

Target Audience: All healthcare professionals including but not limited to physicians, nurse practitioners, pharmacists, and physician assistants.

Continuing medical education credit is NOT associated with this event.

Nirmatrelvir tablets; ritonavir tablets (PAXLOVIDTM)


PAXLOVID is approved for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death; and

The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

Please click the links below to see the Prescribing Information and the Fact Sheet for Healthcare Providers

• Prescribing Information (including BOXED WARNING)
• EUA Fact Sheet for Healthcare Providers